9.96
-0.10%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wanbangde Pharmaceutical Holding Group Co
Its shares trade on Shenzhen under the ticker 002082.SZ. It has been listed since 20 November 2006. In the fiscal year to 31 December 2025, it reported a net loss of CN¥198.8m. At that date it held total assets of CN¥4.39bn and shareholders' equity of CN¥2.52bn.
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in non-ferrous metal industry. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2006-11-20. The firm primarily operates through three segments. The Pharmaceutical Manufacturing segment is mainly engaged in the research and development, production and sales of modern Chinese medicines, chemical raw materials and chemical preparations. The Medical Device segment is mainly engaged in the research and development of medical devices, medical equipment services and provision of hospital engineering services. The firm also conducts its business through the Other segment. The firm conducts its business in the domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Nov 2006
- Employees
- 1,569
- Website
- dongliang.com.cn ↗
Leadership
Pay as last reported
- Mr. Shouming ZhaoChairman of the Board, General Manager, since 2017CN¥980,000
- Ms. Hui ZhuangVice Chairman of the Board, since 2017
- Mr. Tongke LiuDeputy General Manager, Secretary of the Board, Director, since 2017CN¥450,000
- Mr. Bin HanDirectorCN¥40,000
- Mr. Zhenyong JiDirector
- Ms. Hong LinDirector
- Mr. Jian MaDirector
- Mr. Yue CaoIndependent DirectorCN¥100,000
- Ms. Yang LiIndependent Director
- Mr. Yongquan LiIndependent DirectorCN¥100,000
- Mr. Pengfei TuIndependent Director
- Mr. Yuejiang ZhouIndependent DirectorCN¥100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Wanbangde Pharmaceutical Holding Group employs 1,569 full-time employees in Taizhou, China.
- The company operates through three segments including Pharmaceutical Manufacturing and Medical Device.
- Wanbangde's business spans domestic and overseas markets with a focus on modern Chinese medicines.
Weaknesses
- The company's non-ferrous metal industry engagement conflicts with its pharmaceutical sector description.
- Wanbangde's business description mentions non-ferrous metal industry which is inconsistent with its pharmaceutical focus.
- The firm's segments include Other, indicating potential lack of strategic clarity.
Opportunities
- Wanbangde can expand its Pharmaceutical Manufacturing segment into overseas markets.
- The Medical Device segment offers growth potential in healthcare technology services.
- The company's focus on modern Chinese medicines aligns with global health trends.
Threats
- The inconsistency between non-ferrous metal industry and pharmaceutical sector may confuse investors.
- Wanbangde's reliance on domestic markets poses a risk for international expansion.
- The Other segment's vague nature could lead to operational inefficiencies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.